UNSPSC 51373335: Bupivacaine/hydromorphone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373335 Bupivacaine/hydromorphone is a Commodity code that in recent state and local procurement activity does not align with its nominal pharmaceutical scope. The single documented recent opportunity — Seminole County, Florida's IFB60459723LAS posted June 30, 2026 — solicits Naloxone and Safe Drug Deactivation Systems, products unrelated to bupivacaine or hydromorphone formulations. The mismatch suggests either a tagging error in the county's procurement system or a broadening of the code's use that departs from its intended pharmaceutical category. No additional recent state or local solicitations under this code are present in the source.

Seminole County's opportunity represents community health procurement activity, with annual requirements of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems delivered quarterly to the Seminole County Community Health Building in Sanford, Florida. The IFB closed July 26, 2023, with a two-year contract term plus one-year renewal option, fixed-fee pricing, and standard compliance requirements including drug-free workplace certification, E-Verify validation, and workers' compensation and commercial general liability insurance. The procurement notes potential FEMA funding and associated federal compliance obligations. Because the source shows minimal documented activity under this code and the single opportunity's product scope diverges significantly from the code's stated pharmaceutical category, prospecting firms should verify the code's current use within target jurisdictions before committing resources to this category.